Acute Leukemia

More than half of patients with two common acute leukemia subtypes exhibited a clinical response to the investigational therapy revumenib, results of the AUGMENT-101 trial showed.

The FDA granted orphan drug designation to KITE-222, an investigational chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory acute myeloid leukemia.

Patients with acute leukemia or myelodysplastic syndrome in an active state experienced significantly greater COVID-19 severity but not higher mortality due to the virus, according to research presented at ASH Annual Meeting and Exposition.

The FDA approved rituximab in combination with chemotherapy for several pediatric cancer indications.

September is Childhood Cancer Awareness Month.

Minimal residual disease persistence prior to allogeneic hematopoietic stem cell transplant influenced OS and RFS among patients with acute leukemia, according to study results presented at Society of Hematologic Oncology Annual Meeting.

Eunice Wang, MD, has been named medical director of infusion services at Roswell Park Comprehensive Cancer Center.

A baseline risk score predicted HF risk in patients with acute leukemia with factors such as left ventricular ejection fraction, anthracycline dose, age and preexisting CVD, according to a study published in JACC: CardioOncology.

Phase 2 study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in pediatric patients with CD19 expressing relapsed and refractory B-cell acute lymphoblastic leukemia. This study is targeting patients with newly diagnosed B-ALL predicted to have an exceedingly poor outcome with conventional chemotherapy, in high-risk first relapse, or in second or greater relapse.

ASH announced the election of three clinicians to leadership positions within the society.